Biocryst Pharma did it. Aurinia Pharma did not.
The “it” is a successful, commercial drug launch. Biocryst reported a better-than-expected $10.9 million in sales for its drug Orladeyo in the March quarter — the first public assessment of the medicine’s marketing progress since it was approved last December.
Aurinia’s first-quarter report was a disappointment. Its drug, called Lupkynis, managed just $900,000 in sales, although marketing began in February after a January approval.